Another study considered that the p38α/β inhibitor SB202190 could be used as a putative therapy in this type of tumor, in which STK11 could be a critical biomarker for this p38-based therapy, but no genetic evidence supported a critical role for p38β [89]. Here, MAPK11 is linked to neoplasm.